堃博醫療:2021年營業收入同比增長234.2%達1089萬美元, 核心產品InterVapor實現中國商業化
格隆匯3月30日丨2022年3月29日,堃博醫療-B(02216.HK)(以下簡稱“公司”)公佈上市以來首份完整的財年業績報吿。期內,集團獲得收入為10.89百萬美元,較2020年同期增加234.2%,其中,中國內地總收入為6.02百萬美元,相較2020年同期大幅增長了375%。2021年海外收入為4.87百萬美元,佔比45%,相較2020年海外收入同期增長144%。毛利為8.72百萬美元,較2020年同期大幅增加248.8%,毛利率則上升至80.27%。經調整後虧損縮窄。截至2021年底,公司包括現金及現金等價物、等在內的資產總額為2.53億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.